Inherited genetic variant influences response to leukemia treatment for some children
(St. Jude Children's Research Hospital) St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2020 Category: Cancer & Oncology Source Type: news

MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline p...
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves First Maintenance Therapy for AML FDA Approves First Maintenance Therapy for AML
The FDA has approved an oral formulation of azacitidine for the continued treatment of adults with acute myeloid leukemia (AML) who have achieved initial complete remission.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 2, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) September 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 2, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia
FDA approved azacitidine tablets (ONUREG ®, Celgene Corporation) for acute myeloid leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Late Morbidity, Mortality Down for Survivors of Childhood ALL
THURSDAY, Aug. 20, 2020 -- Contemporary survivors of childhood acute lymphoblastic leukemia (ALL) have reduced late morbidity and mortality, according to a study published online July 24 in the Journal of Clinical Oncology. Stephanie B. Dixon,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2020 Category: Pharmaceuticals Source Type: news

Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
Guidance for Industry: Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 13, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
THURSDAY, Aug. 13, 2020 -- Overall survival is longer and the incidence of remission is higher among previously untreated, older patients with acute myeloid leukemia (AML) who receive azacitidine plus venetoclax versus azacitidine alone, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2020 Category: Pharmaceuticals Source Type: news

Azacitidine + Venetoclax Combo Benefits Older Patients With AML Azacitidine + Venetoclax Combo Benefits Older Patients With AML
The treatment regimen improved overall survival and remission rates with rapid responses in the tough-to-treat population of older patients with acute myeloid leukemia (AML).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASH Issues Guidelines on Newly Diagnosed AML in Older Adults
WEDNESDAY, Aug. 12, 2020 -- In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Combination therapy improves survival outcomes for patients with acute myeloid leukemia
(University of Texas M. D. Anderson Cancer Center) A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
August 11, 2020—(BRONX, NY)—Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers atAlbert Einstein College of Medicine,Children’s Hospital at Montefiore (CHAM), andRutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop p...
Source: Einstein News - August 11, 2020 Category: Universities & Medical Training Source Type: news

New study may refine predicted survival outcomes and treatment in younger adults with acute leukemia
(Ohio State University Wexner Medical Center) The findings of a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 5, 2020 Category: Cancer & Oncology Source Type: news

Large international study pinpoints impact of TP53 gene mutations on blood cancer severity
(Memorial Sloan Kettering Cancer Center) A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news

Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
FRIDAY, July 31, 2020 -- Survivors of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) may experience late effects, with a high incidence of subsequent endocrine disease and cardiac disease, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia
(Huntsman Cancer Institute) In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI. When quizartinib was combined with another TKI called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2020 Category: Cancer & Oncology Source Type: news

A spin-off to develop therapies for leukaemia based on CAR-T, by Josep Carreras Institute
(Josep Carreras Leukaemia Research Institute) Invivo Ventures, CDTI-Innvierte (Spanish Ministry of Industry) and the Josep Carreras Foundation have established a first round of funding of € 3,050,000. OCI will carry out three projects, the most advanced of which is a CAR-T CD1a (OCI-1) project for the treatment of cortical T-cell acute lymphoblastic leukemia (coT-ALL), a subtype of leukaemia that mainly affects children and which has a poor prognosis if patients do not respond to standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2020 Category: International Medicine & Public Health Source Type: news

What Are Some Pediatric Oncological Emergencies?
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Don't Overlook Treating Older Patients With APL, Expert Says Don't Overlook Treating Older Patients With APL, Expert Says
A conversation with Dr Heidi Klepin on why this subtype of acute myeloid leukemia is surprisingly treatable in older patients, if quickly identified.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A new nanoconjugate blocks acute myeloid leukemia tumor cells without harming healthy ones
(Universitat Autonoma de Barcelona) The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments. The receptor for this nanoparticle is expressed in 20 types of cancer and associated with a poor prognosis, so this drug could open a new therapeutic pathway for other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2020 Category: Cancer & Oncology Source Type: news

Good Diet May Cut Toxicity Risk in Treatment of Pediatric ALL
TUESDAY, June 30, 2020 -- Diets high in antioxidant-rich foods may cut the risk of developing bacterial infections or mucositis during the first phase of acute lymphoblastic leukemia (ALL) treatment in pediatric patients, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2020 Category: Pharmaceuticals Source Type: news

Treating leukaemia more effectively
(Goethe University Frankfurt) Acute lymphoblastic leukaemia (ALL) is the most common kind of cancer in children. T-ALL, a subtype that resembles T-lymphocytes, can be treated successfully with the drug nelarabine. The drug has not been successful, however, with B-ALL, a subtype resembling B-lymphocytes. This has puzzled oncologists sinced the 1980's. Now, an international research team headed by Goethe University and the University of Kent has discovered the reason: B-ALL cells contain the enzyme SAMHD1, which deactivates the drug. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 24, 2020 Category: Biology Source Type: news

Oncotarget: RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation
(Impact Journals LLC) The cover for issue 25 of Oncotarget features Figure 8, 'BI-D1870 in combination with vincristine increase metaphase arrest and apoptosis synergistically,' by Chae, et al. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news

Cancer drug cures COVID-19 patient with acute respiratory distress
(Philipps-Universit ä t Marburg) A successfully treated case at the Marburg University Medical Center is raising hope for a COVID-19 cure: The team has successfully used the cancer drug ruxolitinib for the first time to cure a patient suffering from acute respiratory distress syndrome (ARDS) after infection with the coronavirus SARS-CoV-2. Oncologist Professor Dr. Andreas Neubauer and his colleagues report on the successfully treated case in the scientific journal Leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 18, 2020 Category: Cancer & Oncology Source Type: news

Call for caution for using a CAR-T immunotherapy against acute myeloid leukemia
(Josep Carreras Leukaemia Research Institute) Researchers from the Josep Carreras Leukaemia Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2020 Category: Cancer & Oncology Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Media News - June 13, 2020 Category: Pharmaceuticals Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Investor Update - June 13, 2020 Category: Pharmaceuticals Source Type: news

What if child maltreatment were childhood leukemia? Lessons from the halls of the hospital - Babcock P.
This article examines lessons that can be applied to prevention, research, training, and clinical treatment in child welfare from analogous experiences in combatting childhood acute lymphoblastic leukemia (ALL). Since the 1960s, childhood cancer researcher... (Source: SafetyLit)
Source: SafetyLit - June 9, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Leukemia immune profiles predict drug resistance and benefits of immunotherapy
(American Association for the Advancement of Science) By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), researchers have identified new immune classes of the disease that predict the likelihood of drug resistance and positive responses to immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2020 Category: Cancer & Oncology Source Type: news

$2 million SBIR grant fast-tracks cancer drug platform technology
(Purdue University) A $1,999,998 SBIR Phase I/II grant from the National Institute of Cancer to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform aimed at treating relapse for acute myeloid leukemia and other diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2020 Category: Cancer & Oncology Source Type: news

Courtney DiNardo, MD, on Need for Improved, Effective Regimens in IDH1-Positive AML
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Courtney DiNardo, MD Source Type: news

AMG 330 Appears Safe, Tolerable in Relapsed/Refractory Acute Myeloid Leukemia
The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
(University of Texas M. D. Anderson Cancer Center) A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL
A universal chimeric antigen receptor (CAR) T-cell therapy produced responses in adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) in initial findings from an ongoing study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Genetic Factors in AML With Myelodysplasia-Related Changes Genetic Factors in AML With Myelodysplasia-Related Changes
This study explored the clinical significance of three subcategories of AML-MRC.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Dexrazoxane Preserved Cardiac Function in Children Undergoing Chemotherapy for AML
A study found that dexrazoxane, a cardioprotective drug, preserved cardiac function without compromising overall survival and event-free survival for pediatric patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo
A new analysis of 8300 patients with ALL undergoing chemotherapy revealed that secondary ALL is common, and the prolonged long-term survival rate is 30% to 50%. Women had a lower risk of death than men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show t...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

AML:'Start as Oncology Patients, but Return With Heart Damage'AML:'Start as Oncology Patients, but Return With Heart Damage '
Children treated for acute myeloid leukemia are often cured of their cancer but return years later with hearts damaged by therapy. Cardioprotection with dexrazoxane could help, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Dexrazoxane Preserves Cardiac Function in Pediatric Leukemia
TUESDAY, May 12, 2020 -- For pediatric patients with acute myeloid leukemia (AML), dexrazoxane preserves cardiac function without affecting survival, according to a study published online April 28 in the Journal of Clinical Oncology. Kelly D. Getz,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 12, 2020 Category: Pharmaceuticals Source Type: news

More selective elimination of leukemia stem cells and blood stem cells
(University of Zurich) Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia. However, the side effects of therapies are often severe. A group of researchers led by the University of Zurich have now shown how human healthy and cancerous hematopoietic stem cells can be more selectively eliminated using immunotherapy instead of chemotherapy in mice. The aim is to test the new immunotherapy in humans as soon as possible. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2020 Category: Biology Source Type: news

First-in-Human Trial of TruUCAR GC027 in Relapsed/Refractory T-Cell ALL Announced
The first-in-human clinical trial for TruUCAR GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia was announced by Gracell Biotechnologies. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

EU Panel OKs Glasdegib for AML & Luspatercept for MDS EU Panel OKs Glasdegib for AML & Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 1, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

EU Panel OKs Glasdegib for AML and Luspatercept for MDS EU Panel OKs Glasdegib for AML and Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Grants Priority Review to CC-486 for the Treatment of Acute Myeloid Leukemia
The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb ’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) May 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486, an investigational oral hypomethylating agent,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 1, 2020 Category: Drugs & Pharmacology Source Type: news